Developing a Scale for Home-Visit Nurses to Start End-of-life Discussions with Cancer Patients.

Context: Home-visit nurses find it challenging to determine the appropriate time to initiate end-of-life discussions with cancer patients.

Objective: This study aimed to develop the Timing of End-of-Life Discussions (T-EOLD) scale to help home-visit nurses determine the appropriate time to initiate end-of-life discussions with cancer patients and to test its reliability and validity.

Methods: The scale items were developed based on qualitative data extracted from interviews, literature reviews, and expert panel discussions.

When should Home-visit nurses initiate end-of-life discussions for patients with Organ failure and family caregivers? A qualitative study.

Background: End-of-life (EOL) discussions for organ-failure patients with family caregivers are important factors for successful EOL care. However, identifying the appropriate time to initiate these discussions is difficult owing to the unpredictability of the disease trajectory. No practical tools or clinical indicators currently exist that can help identify non-cancer patients receiving home care who need EOL discussions.

Timely Identification of Patients With Cancer and Family Caregivers in Need of End-of-Life Discussions by Home-Visit Nurses in Japan: A Qualitative Descriptive Study.

End-of-life (EOL) discussions for patients with cancer are a key factor of successful EOL care; however, identifying the optimal timing for these discussions in Japanese home-care settings is difficult. To identify the time at which patients with cancer and their caregivers need EOL discussions, we explored when home-visit nurses start EOL discussions. We interviewed 23 home-visit nurses and analyzed the data using qualitative content analysis.

[Regorafenib and Trifluridine and Tipiracil Hydrochloride Can Potentially Improve the Survival Time for Patients with Advanced or Recurrent Colorectal Cancer].

Regorafenib and trifluridine and tipiracil hydrochloride(TFTD)have been recently used for the treatment of advanced or recurrent colorectal cancer during or after the third-line therapy. These drugs are expected to prolong survival. The progression- free survival period associated with each drug in clinical trials is known to be less than 2 months.